Skip to main content
Clinical Trials/NCT06050070
NCT06050070RecruitingNot Applicable

Targeting Large-scale Networks in Depression With Real-time fMRI Neurofeedback

University of Michigan2 sites in 1 country58 target enrollmentStarted: March 18, 2024Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
58
Locations
2
Primary Endpoint
Blood Oxygen Level Dependent (BOLD) signal change during the active > passive contrast during the localizer session

Study Overview

Brief Summary

The purpose of this study is to develop a technique called real time fMRI neurofeedback.

This technique uses a regular MRI scanner, except that special software allows the researchers to measure activity in participants brain, using fMRI, and then give information, in the form of a feedback signal, which indicates brain activity in real time, while in the MRI scanner. The larger goal of this study is to develop ways to help people, including those with depression, better regulate brain activity. The researchers think that this may be helpful in managing psychiatric symptoms.

This study design has three phases, however, only two phases (phase 2 and 3) are considered to be a clinical trial. Phase 2 (part 2) was registered and is NCT05934604. This is the phase 3 (part 3) for this project and is funded by the National Institutes of Health.

Detailed Description

Part 3/Phase 3 study hypothesis are:

  • Rest Focus Task (RFT) will activate brain networks at the individual subject level to provide a viable signal for Neurofeedback (NF)
  • At the group level, RFT in the Active>Passive contrast will activate canonically defined salience network
  • Neurofeedback-reinforced practice over the session will increase RFT activation over the course of the training session, comparing RFT activation, without NF, before and after NF runs.
  • Valid Neurofeedback will increase RFT activation more compared to sham NF (assessed during the no-NF session).

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Basic Science
Masking
Double (Participant, Care Provider)

Eligibility Criteria

Ages
18 Years to 55 Years (Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Meets The Diagnostic and Statistical Manual of Mental Disorders five (DSM5) criteria for Major Depressive Disorder, single or recurrent, active or in partial remission
  • •Patient Health Questionnaire (PHQ9) greater or equal (≥)6, and approximately (~) 50% with PHQ9≥10
  • •If participants are taking antidepressant medications, on stable dosage for 4 weeks
  • •No history of active substance use disorder in the past 6 months
  • •Absence of suicidal thoughts with plans or intentions, as assessed by Columbia Suicide Severity Rating Scale (C-SSRS)
  • •If a woman of child-bearing age, not pregnant or trying to become pregnant
  • •Ability to tolerate small, enclosed spaces without anxiety
  • •No metals, implants or metallic substances within or on the body that might cause adverse effects to the subject in a strong magnetic field, or interfere with image acquisition, e. g. aneurysm clips, retained particles (for example metal workers with exposures, protocol has more details), etc.
  • •Size compatible with scanner gantry (per protocol)
  • •Ability and willingness to give informed consent to participate.

Exclusion Criteria

  • •Size not compatible with scanner
  • •Not meeting diagnostic criteria for bipolar disorder, schizophrenia, other psychosis, obsessive-compulsive disorder, active eating disorder or Post-traumatic stress disorder (PTSD)
  • •No history of serious neurological illness (including, but not limited to, seizures/epilepsy) or current medical condition that could compromise brain function, such as liver failure
  • •No history of closed head injury, e. g. loss of consciousness > ~5 min, hospitalization, neurological sequela

Arms & Interventions

Real-time neurofeedback

Experimental

Subjects will complete three visits with one or two fMRI sessions after initial assessment and training visit. The first session will be to introduce practice tasks using the mock scanner. In the second visit participants will have an fMRI. The study team will review the fMRI results to decide if participants will continue on the study (must exhibit a specific pattern of activation) and have the second fMRI at the third visit.

Intervention: FMRI with real time feedback (Other)

Sham controlled feedback

Sham Comparator

Subjects will complete three visits with one or two fMRI sessions after initial assessment and training visit. The first session will be to introduce practice tasks using the mock scanner. In the second visit participants will have an fMRI. The study team will review the fMRI results to decide if participants will continue on the study (must exhibit a specific pattern of activation) and have the second fMRI at the third visit.

Intervention: FMRI with sham controlled feedback (Other)

Outcomes

Primary Outcomes

Blood Oxygen Level Dependent (BOLD) signal change during the active > passive contrast during the localizer session

Time Frame: Approximately 40 minutes (during MRI)

Using standard pre-processing pipelines, the general linear model, convolved with the hemodynamic response function, will be used to predict change in BOLD signal for the contrast of the active compared to the passive conditions. Z-transformed t-statistics will be corrected for multiple comparisons in the region of interest (salience network)

BOLD signal change during the active>passive contrast, comparing baseline with transfer runs (no NF in either), during the real time functional magnetic resonance imaging neurofeedback (rtfMRI-NF) session

Time Frame: Approximately 40 minutes (during MRI)

Same processing as outcome measure 2, except the contrast of active\>passive will itself be contrasted within the session (baseline compared to transfer run)

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Stephan F. Taylor

Professor of Psychiatry

University of Michigan

Study Sites (2)

Loading locations...

Similar Trials